Alteration of neurotensin receptors in MPTP-treated mice

Peptides

Volumn 20, Issue 7, 1999, Pages 803-807

  Tanji, Hiroaki ^a   Araki, Tsutomu ^a   Fujihara, Kazuo ^a   Nagasawa, Haruo ^b   Itoyama, Yasuto ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIYAGI UNIVERSITY   (Japan)

Author keywords

Dopamine uptake sites; Mouse; MPTP; Neurotensin receptor; Receptor autoradiography

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MAZINDOL; NEUROTENSIN; NEUROTENSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; AUTORADIOGRAPHY; CORPUS STRIATUM; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; KINETICS; MALE; MAZINDOL; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROTENSIN; NEUROTOXINS; PARKINSON DISEASE; RECEPTORS, NEUROTENSIN; SUBSTANTIA NIGRA;

EID: 0032813186     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00065-0     Document Type: Article

References (41)

1. Araki T., Kato H., Shuto K., Fujiwara T., Itoyama Y. Effect of aging on dopaminergic receptors and uptake sites in the rat brain studied by receptor autoradiography. J Neurol Sci. 148:1997;131-137.
2. Araki T., Tanji H., Kato H., Itoyama Y. Sequential changes of dopaminergic receptors in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle. J Neurol Sci. 160:1998;121-127.
3. Bayer V.E., Towle A.C., Pickel V.M. Ultrastructural localization of neurotensin-like immunoreactivity within dense core vesicles in perikarya, but not terminals, colocalizing tyrosine hydroxylase in the rat ventral tegmental area. J Comp Neurol. 311:1991;179-196.
4. Berger K., Przedborski S., Cadet J.L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull. 26:1991;301-307.
5. Bezard E., Dovero S., Bioulac B., Gross C.E. Kinetics of nigral degeneration in chronic model of MPTP-treated mice. Neurosci Lett. 234:1997;47-50.
6. Bieganowska K., Czlonkowska A., Bidzinski A., Mierzewska H., Korlak J. Immunological changes in the MPTP-induced Parkinson's disease mouse model. J Neuroimmunol. 42:1993;33-38.
7. Burgevin M.C., Castel M.N., Quarteronet D., Chevet T., Laduron P.M. Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport. Neuroscience. 49:1992;627-633.
8. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methy-4-phenyl-1,2,3,6-tetrahydropyridine . Proc Natl Acad Sci USA. 80:1983;4546-4550.
9. 3H]neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections evidence from a receptor autoradiographic study . Brain Res. 564:1991;37-44.
10. Chinaglia G., Probst A., Palacios J.M. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy an autoradiographic study in basal ganglia . Neuroscience. 39:1990;351-360.
11. Donnan G.A., Willis G.L., Kaczmarczyk S.J., Rowe P. Motor function in the 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J Neurol Sci. 77:1987;185-191.
12. Emson P.C., Goedert M., Horsfield P., Rioux F., St. Pierre S. The regional distribution and chromatographic characterization of neurotensin-like immunoreactivity in the rat central nervous system. J Neurochem. 38:1982;992-999.
13. Faggin B.M., Zubieta J.K., Rezvani A.H., Cubeddu L.X. Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. J Pharmacol Exp Ther. 252:1990;817-825.
14. Goedert M., Pittaway K., Emson P.C. Neurotensin receptors in the rat striatum lesion studies . Brain Res. 299:1984;164-168.
15. Hallman H., Lange J., Olson L., Strömberg I., Jonsson G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. J Neurochem. 44:1985;117-127.
16. 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain. Proc Natl Acad Sci. USA. 83:1986;6203-6207.
17. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methy-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
18. Hirata Y., Nagatsu T. Early and late effects of systemically administrated 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on tyrosine hydroxylase activity in vitro and on tyrosine hydroxylation in tissue slices of mouse striatum. Neurosci Lett. 68:1986;245-248.
19. 3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol Pharmacol. 26:1984;35-44.
20. 3H]mazindol autoradiography. J Neurosci. 5:1985;1513-1521.
21. Jenner P., Rupniak N.M.J., Rose S., Kelly E., Kilpatrick G., Lees A., Marsden C.D. 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett. 50:1984;85-90.
22. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev. 18:1993;75-113.
23. Kasckow J., Nemeroff C.B. The neurobiology of neurotensin focus on neurotensin-dopamine interactions . Regul Pept. 36:1991;153-164.
24. Kitabgi P. Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways. Neurochem Int. 14:1989;111-119.
25. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
26. Mai J.K., Triepel J., Metz J. Neurotensin in the human brain. Neuroscience. 22:1987;499-524.
27. Palacios J.M., Kuhar M.J. Neurotensin receptors are located on dopamine-containing neurons in rat midbrain. Nature. 294:1981;587-589.
28. Przedborski S., Kostic V., Jackson-Lewis V., Cadet J.L., Burke R.E. Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on dopamine D1 and D2 receptors and uptake sites a quantitative autoradiographic study . J Neurochem. 57:1991;1951-1961.
29. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
30. Quirion R., Chiueh C.C., Everist H.D., Pert A. Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals. Brain Res. 327:1985;385-389.
31. 3H]neurotensin receptors in rat brain visualization by tritium-sensitive films . Peptides. 3:1982;757-763.
32. Quirion R., Welner S., Gauthier S., Bédard P. Neurotensin receptor binding sites in monkey and human brain autoradiographic distribution and effects of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine treatment . Synapse. 1:1987;559-566.
33. Sadoul J.L., Chécler F., Kitabgi P., Rosténe W., Javoy-Agid F., Vincent J.P. Loss of high affinity neurotensin receptors in substantia nigra from Parkinsonian subjects. Biochem Biophys Res Commun. 125:1984;395-404.
34. Schotte A., Rosténe W., Laduron P.M. Different subcellular localization of neurotensin-receptor and neurotensin-acceptor sites in the rat brain. J Neurochem. 50:1988;1026-1031.
35. Sidman R.L., Angevine J.B., Pierce E.T. Atlas of the mouse brain and spinal cord. 1971;Harvard University Press, Cambridge, MA.
36. Sonsalla P.K., Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol. 129:1986;339-345.
37. Studler J.M., Kitabgi P., Tramu G., Herve D., Glowinski J., Tassin J.P. Extensive colocalization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides. 11:1988;95-100.
38. Uhl G.R., Whitehouse P.J., Price D.L., Tourtelotte W.W., Kuhar M.J. Parkinson's disease depletion of substantia nigra neurotensin receptors . Brain Res. 308:1984;186-190.
39. Waters C.M., Hunt S.P., Jenner P., Marsden C.D. Localization of neurotensin receptors in the forebrain of common marmoset and the effects of treatment with the neurotoxin 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 412:1987;244-253.
40. Widerlöv E., Kilts C.D., Mailman R.B., Nemeroff C.B., McCown T.J., Prange A.J. Jr, Breese G.R. Increase in dopamine metabolites in rat brain by neurotensin. J Pharmacol Exp Ther. 223:1982;1-6.
41. Willis G.L., Donnan G.A. Histochemical, biochemical and behavioral consequences of MPTP treatment in C-57 black mice. Brain Res. 402:1987;269-274.